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Paroxysmal kinesigenic dyskinesias is a paroxysmal movement disorder characterized by recurrent, brief attacks of abnormal
involuntary movements induced by sudden voluntary movements. Although several loci, including the pericentromeric region of
chromosome 16, have been linked to paroxysmal kinesigenic dyskinesias, the causative gene has not yet been identiﬁed. Here,
we identiﬁed proline-rich transmembrane protein 2 (PRRT2) as a causative gene of paroxysmal kinesigenic dyskinesias by using
a combination of exome sequencing and linkage analysis. Genetic linkage mapping with 11 markers that encompassed the
pericentromeric of chromosome 16 was performed in 27 members of two families with autosomal dominant paroxysmal
kinesigenic dyskinesias. Then, the whole-exome sequencing was performed in three patients from these two families. By
combining the deﬁned linkage region (16p12.1–q12.1) and the results of exome sequencing, we identiﬁed an insertion mutation
c.649_650InsC (p.P217fsX7) in one family and a nonsense mutation c.487C4T (p.Q163X) in another family. To conﬁrm our
ﬁndings, we sequenced the exons and ﬂanking introns of PRRT2 in another three families with paroxysmal kinesigenic dys-
kinesias. The c.649_650InsC (p.P217fsX7) mutation was identiﬁed in two of these families, whereas a missense mutation,
c.796C4T (R266W), was identiﬁed in another family with paroxysmal kinesigenic dyskinesias. All of these mutations com-
pletely co-segregated with the phenotype in each family. None of these mutations was identiﬁed in 500 normal unaffected
individuals of matched geographical ancestry. Thus, we have identiﬁed PRRT2 as the ﬁrst causative gene of paroxysmal
kinesigenic dyskinesias, warranting further investigations to understand the pathogenesis of this disorder.
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Introduction
Paroxysmal kinesigenic dyskinesias (PKD) is a relatively rare neuro-
logical disorder of unknown cause. The characteristic of PKD is
recurrent and brief attacks of involuntary movements that
are triggered by sudden voluntary movements (Kertesz, 1967;
Goodenough et al., 1978; Demirkiran and Jankovic, 1995; Bruno
et al., 2004).The episodes usually present with dystonia, chorea,
athetosis, ballism or their combination. The attacks usually last
from a few seconds to a few minutes. During the attacks, there
is absolutely no loss or alteration of consciousness. However, the
prognosis of PKD is favourable and the patients usually show
excellent responses to antiepileptic drugs (Kertesz, 1967;
Goodenough et al., 1978; Houser et al., 1999; Lotze and
Jankovic, 2003; Bruno et al., 2004). It is noteworthy that in
some patients or their ﬁrst- and second-degree relatives, PKD is
often combined with other intermittent neurological disorders, like
infantile convulsions or infantile convulsion and choreoathetosis
(Tomita et al., 1999; Swoboda et al., 2000; Bruno et al., 2004).
PKD can be classiﬁed as primary or secondary according to its
aetiology (Goodenough et al., 1978; Demirkiran and Jankovic,
1995; Blakeley and Jankovic, 2002). Most of the cases with
secondary PKD are caused by multiple sclerosis, head injury, meta-
bolic derangements or cerebral perfusion insufﬁciency (Blakeley and
Jankovic, 2002; Perona-Moratalla et al., 2009). Primary PKD can be
further classiﬁed as idiopathic or familial PKD according to the her-
editary nature. Familial PKD cases are the most common and are
usually inherited in an autosomal dominant manner (Goodenough
et al., 1978; Demirkiran and Jankovic, 1995; Marsden, 1996;
Perona-Moratalla et al., 2009). Tomita et al. (1999) performed a
genome-wide linkage and haplotype analysis in eight Japanese
families and assigned the ﬁrst PKD-critical region to a region
between D16S3093 and D16S416. They named this 12.4cM
region at 16p11.2–q12.1 as EKD1 (episodic kinesigenic dyskinesias
1). In the following years, a number of other linkage studies on a
variety of ethnicities conﬁrmed EKD1, which encompassed the peri-
centromeric of chromosome 16 and shared a minimum overlap
region between D16S3093 and D16S3396 (Bennett et al., 2000;
Swoboda et al., 2000; Cuenca-Leon et al., 2002; Kikuchi et al.,
2007; Wang X et al., 2010). Moreover, two other regions that
did not overlap with EKD1 were also identiﬁed and deﬁned as
EKD2 (16q13–q22.1) and EKD3, respectively (Valente et al.,
2000; Spacey et al., 2002). Nevertheless, no causative gene of
PKD has been identiﬁed thus far.
A recently developed technology using whole-exome capture
and high-throughput sequencing provides a powerful and afford-
able means to identify disease-causing genes. Recent studies have
demonstrated the sensitivity and accuracy of the exome-sequen-
cing approach in the identiEcation of the causal genes of several
rare monogenic diseases such as Miller syndrome (Ng et al., 2010)
and Bartter syndrome (Choi et al., 2009). In 2010, we identiﬁed
transglutaminase 6 as a novel causative gene of spinocerebellar
ataxias using the combined strategy of exome sequencing and
linkage analysis (Wang JL et al., 2010). Here, we applied a similar
strategy to screen the causative gene of PKD.
Materials and methods
Families and patients
This study was approved by the Expert Committee of Xiangya Hospital
of the Central South University in China (equivalent to an Institutional
Review Board). Written informed consent was obtained from all
subjects.
Five Chinese Han PKD families presenting as autosomal dominant
inheritance were included. A total of 75 members including 24 patients
with PKD were enrolled. Families A and B were PKD pedigrees asso-
ciated with other intermittent neurological disorders, in which both
Patients III: 2 and III: 5 in Family A as well as Patients III: 3 and III:
5 in Family B were diagnosed with infantile convulsion and chor-
eoathetosis syndrome. Families C–E were PKD pedigrees without any
other paroxysmal conditions such as epilepsy, migraine or episodic
ataxia. Among the 24 patients, the mean age at onset of the disease
was 9.6 years (range 4–18 years). Attacks were usually precipitated by
sudden movements, intention to move, startles, stress and anxiety.
The symptoms of attacks consisted of dystonia, chorea and athetoid
movements. The duration of the entire attack lasted from a few se-
conds to 1min. Neither loss nor impairment of consciousness was
observed in the attacks. Neurological examinations and imaging ﬁnd-
ings between attacks were entirely normal.
All the available affected individuals were subjected to a thorough
neurological examination by two or more experienced neurologists.
Clinical data were collected by interviews and clinical questionnaires,
and the diagnosis of PKD was determined according to the criteria
designed by Bruno et al. (2004). Individuals were diagnosed with in-
fantile convulsions if they experienced non-febrile convulsions at the
age of 3–12 months (Rochette et al., 2008). Infantile convulsion and
choreoathetosis syndrome diagnoses were made according to
Szepetowski et al. (1997). Unaffected individuals (n = 500) of matched
geographic ancestry were also included as healthy controls. Genomic
DNA was prepared from venous blood by standard procedures.
The ﬁrst set of analyses was performed in Families A and B (Fig. 1).
A total of 11 subjects (Patients I: 1–2; II: 1, 3–6; III: 1–2, 4–5) in
Family A and 16 subjects (Patients I: 1–2; II: 1–7; III: 1–7) in Family
B were included in the linkage study. Three individuals (Patient II: 4 in
Family A, Patients II: 2 and II: 4 in Family B) were studied with exome
sequencing. Three additional unrelated autosomal dominant PKD pedi-
grees (Families C–E) were used for subsequent mutational screening.
Genotyping for linkage analysis
Genotyping was performed using 11 microsatellite markers
(D16S3041, D16S403, D16S401, D16S409, D16S3136, D16S2623,
D16S419, D16S415, D16S3057, D16S514, D16S503) in chromosome
16 with primers tagged with ﬂuorescence (HEX, FAM). The markers
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described (Tang et al., 2004). Relative positions were derived from
the human genome draft sequence and the Marshﬁeld map (www.
ncbi.nlm.nih.gov). Two-point logarithm of odds scores were calculated
using Linkage 5.2 package, with the assumptions that, in the two
families, PKD is inherited in an autosomal dominant mode with 95%
penetrance, that the frequency of the mutant allele is 0.0001, and that
the allele frequency of each marker locus is equal (Lathrop and
Lalouel, 1984; Dib et al., 1996). The haplotype in the two pedigrees
was reconstructed manually using the Cyrillic program.
Exome sequencing
Library preparation and exome sequencing
Qualiﬁed genomic DNA extracted from the three patients (Patient II: 4
from Family A, Patients II: 2 and II: 4 from Family B) was sheared by
sonication and then hybridized to the SureSelect Biotiny lated RNA
Library (BAITS) for enrichment, according to the manufacturer’s in-
structions. The enriched library targeting the exome was sequenced
on the HiSeq 2000 platform to get paired-end reads with read length
of 90bp.
Alignment, single-nucleotide polymorphism and
insertions or deletions calling
The sequenced reads were aligned to the human genome reference
(UCSC hg 18 version) using SOAPaligner (Li et al., 2008). Those reads
were then aligned in the designed target regions and were collected
for single-nucleotide polymorphism (SNP) calling and subsequent ana-
lysis. We estimated the consensus genotype and quality by SOAPsnp
(v 1.03) (Li et al., 2010). The low-quality variations were ﬁltered out
by the following criteria: (i) consensus quality score 520 (Q20);
(ii) average copy number at the allele site 52; (iii) distance of two
adjacent SNPs 55bp; and (iv) sequencing depth 54o r4500. For
insertions or deletions (indels) in the targeted exome regions, we
aligned the reads to the reference genome using bwa. The alignment
result was used to identify the breakpoints by gatk. Finally, we anno-
tated the genotypes of insertions and deletions (Li and Durbin, 2010).
Analysis protocol for exome-sequencing results
Based on the hypothesis that the mutation underlying families with
PKD should not be present in the general population, non-
synonymous/splice acceptor and donor site/insertions or deletions
(NS/SS/Indel) variants reported in the dbSNP (http://www.ncbi.nlm.
nih.gov/projects/SNP/, Build 129), eight previously exome-sequenced
HapMap samples (‘HapMap 8’) and 1000 Genome Project (http://
www.ncbi.nlm.nih.gov/Ftp/) were removed. Synonymous changes
were identiﬁed and ﬁltered from the variant list using SIFT software
(version 4.0, http://sift.jcvi.org/).
Moreover, we only focused on the genes with NS/SS/Indel variants
occurring in the linkage region. We further assumed that all three
exome-sequenced patients should show NS/SS/Indel variants in the
same gene, although the NS/SS/Indel variants might not be identical
in all patients. Sanger sequencing using customized primers was
Figure 1 Linkage analysis of Families A and B mapped the PKD to a region on chromosome 16p12.1-q12.1. The partial pedigrees of
Families A and B were shown and haplotype analysis was indicated on chromosome 16 using 11 markers. The haplotype assumed to carry
the disease allele is indicated with black bars. The haplotype with recombination event is indicated with black and white bars. Subjects in
Families A and B are identiﬁed by the Arabic numerals above the symbol; and the Roman numerals denote the generations. Open
symbols = unaffected; ﬁlled symbols = affected; symbols with a diagonal line = deceased subjects; squares = male; circles = female;
arrow = the proband; minus = wild-type allele; plus = mutant allele; NG = not genotyped.
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affected subjects and to screen the unaffected members in Families
A and B for co-segregation analysis. We then sequenced all the exons
and ﬂanking introns of the PRRT2 gene (NM_145239) in patients
of three additional families (Families C–E) to detect other mutation
sites using the traditional method. As an additional step, the detected
variants were sequenced in 500 neurologically normal control subjects.
Results
The clinical characteristics of families
with paroxysmal kinesigenic
dyskinesias
Detailed clinical characteristics are summarized in Table 1. The ﬁve
families in our study shared some common features of PKD such
as trigger and duration of attack, no loss of consciousness during
attack and good response to treatment with anticonvulsants.
Besides these features, the ﬁve families also presented with a
wide spectrum of clinical heterogeneity. The onset age of the
patients in Families A and C–E was 10 years old, while some
patients in Family B (Patients III: 3 and III: 5) were younger (4 and
5 years old). The characteristics of the attacks varied not only
between families but also among individuals in the same family.
For example, there were two members separately diagnosed with
infantile convulsion and choreoathetosis syndrome in infancy in
Family A (Patients III: 2 and III: 5) and Family B (Patients III: 3
and III: 5). The main manifestation in Family A was dystonia,
choreoathetosis or athetosis, while dystonia were predominant in
Family B. We noted that dystonia of the upper limbs was more
obvious in Family D, while in Family C lower limbs were more
likely to be involved and the patients tended to fall down when
attacks occurred. Although sudden movements induced attacks in
all cases, there may have been some other triggers such as anx-
iety, startle and intention to move in a relatively smaller number of
patients.
Linkage mapping of the syndrome
to chromosome 16p12.1-q12.1
Two-point logarithm of odds scores are shown in Table 2. A max-
imum two-point logarithm of odds score of 3.77 (y = 0) was ob-
tained at mark D16S409, when penetrance was assumed to be
0.95. The highest probability haplotype in Families A and B was
reconstructed manually using the Cyrillic program (Fig. 1) and
some key recombinant events were identiﬁed. In Family A, recom-
bination was present between D16S403 and D16S401 in the short
arm as well as between D16S2623 and D16S419 in the long arm
Table 1 Clinical features in 24 affected members from the ﬁve PKD families
Patient
and sex
Patient age (years) Features of PKD
At
present
At
onset
At
remission
Trigger Sensory
aura
Duration
of attacks
(second)
Involuntary
movement
Response to
anticonvulsants
History
of IC
(month)
EEG CT or
MRI
scan
A(I: 1), M 65 18 520 SM No 55 D No treatment None – –
A(II: 4), F 41 10 25–26 SM No 55 D/A No treatment None – –
A(II: 6), M 39 6 Current SM/S Yes 10–60 D/C PHT(+) None Normal –
A(III: 2), M 19 10 Current SM/S Yes 530 D/C CBZ(+) 6–24 Normal Normal
A(III: 5), F 18 10 Current SM/An No 55 A CBZ(+) 12–24 Normal Normal
B(I: 2), F 63 13 20 SM No 530 D No treatment None – –
B(II: 2), M 41 10 26 SM No 55 D No treatment None Normal Normal
B(II: 4), M 38 8 28 SM No 530 D No treatment None – –
B(II:7), F 36 8 25 SM No 30–60 D No treatment None Normal Normal
B(III: 1), F 19 16 Current SM/S No 530 D CZ(+) None – –
B(III: 3), M 6 4 Current SM No 55 D CBZ/CZ(+) 6–24 Normal Normal
B(III: 5), M 7 5 Current SM No 55 D CBZ/CZ(+) 6–24 Normal Normal
C(II: 3), M 59 10 29 SM/S/IM Yes 530 D/C No treatment None – –
C(II: 6), F 52 9 24 SM/S/IM Yes 30–60 D No treatment None – –
C(II: 10), M 50 9 25 SM/S/IM Yes 530 D/C No treatment None – Normal
C(II: 11), M 47 10 30 SM/S/IM Yes 530 D CBZ(+) None Normal Normal
C(III: 17), F 19 8 Current SM/S/IM Yes 30–60 D CBZ(+) None Normal Normal
C(III: 19), F 16 9 Current SM/IM Yes 530 D/C CBZ(+) None Normal Normal
D(II: 1), M 48 8 23 SM/IM No 530 D/C PHT/PB(+) None Normal –
D(II: 8), F 43 10 25 SM No 530 D No treatment None – –
D(III: 1), M 26 9 35 SM/IM No 530 D/C CBZ(+) None Normal Normal
D(III: 3), M 21 13 Current SM/IM Yes 530 D/C CBZ(+) None Normal Normal
E(I: 2), F 48 8 23 SM No 55 D No treatment None – –
E(II: 1), F 22 10 Current SM Yes 530 D CBZ(+) None Normal Normal
F = female; M = male; SM = sudden movement; S = stress or startle; IM = intention to move; An = anxiety; D = dystonia; C = choreoathetosis; A = athetosis;
CBZ = carbamazepine; PHT = phenytoin; PB = phenobarbital; CZ = clonazepam.
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gene in Family A was located in a region between D16S403 and
D16S419.
In Family B, recombination was observed between D16S401
and D16S409 in the short arm, as well as between D16S3057
and D16S514 in the long arm of chromosome 16 in Patient II:
7. While the unaffected descendents (Patient III: 6) of this patient
carried partial haplotype with recombination near D16S2623
and D16S3057, suggesting the candidate risk gene in Family B
was located in a region between D16S401 and D16S2623.
Together with the results of Family A, a single haplotype between
D16S401 and D16S2623 co-segregated with the phenotype in all
examined patients with PKD in these two families (Fig. 1).
Therefore, the haplotype analyses traced PKD to chromosome
16p12.1-q12.1 with a maximum two-point logarithm of odds
score of 3.77(y = 0).
Exome sequencing identiﬁed PRRT2 as
the candidate gene
To identify the causative gene of PKD, exome sequencing was
performed on DNA samples obtained from three affected mem-
bers of Families A and B (Fig. 1: Patient II: 4 in Family A, Patients
II: 2 and II: 4 in Family B). We generated an average of 6.82Gb of
sequence from each affected individual as paired-end, 90-bp
reads; 6.15Gb (90.18%) passed the quality assessment and
were aligned to the human reference sequence; and an average
of 3.62 Gb of sequence data was mapped to the target region.
After SNPs and Indels calling, we identiﬁed a mean of 96645
variants from the reference sequence per subject, in which an
average of 10756 NS/SS/Indel variants were detected in each
of the PKD patients sequenced. Given that this is a rare disorder,
it is unlikely that causative variants will be present in the general
population. We therefore removed the NS/SS/Indel variants
reported in the dbSNP129, ‘HapMap 8’ and the SNP release of
the 1000 Genome Project. After this initial ﬁlter, we generated an
average of 612 NS/SS/Indel variants from each patient. We then
focused on the genes with NS/SS/Indel variants occurring in the
linkage region (16p12.1-q12.1). During this step, we identiﬁed
ﬁve, three and ﬁve NS/SS/Indel variants from Patient II: 4 in
Family A, and Patients II: 2 and II: 4 in Family B, respectively.
Finally, we assumed that all three patients should show NS/SS/
Indel variants in the same gene. As a result, PRRT2 was found to
be the sole gene with mutations occurring in all three patients
(Fig. 3F). The mutations included an insertion mutation
c.649_650InsC (p.P217fsX7) in Family A, and a nonsense muta-
tion c.487C4T (p.Q163X) in Family B. The mutations were
conﬁrmed by Sanger sequencing (Fig. 3B and C).
Mutation in PRRT2 gene
As shown in Fig. 3E, the PRRT2 gene consists of four exons and its
protein has two domains: two low complexity segments followed
by two transmembrane segments located at amino acids 268–290
and 315–337, respectively. The c.649_650InsC (p.P217fsX7) mu-
tation is a frameshift mutation, which generates a different se-
quence starting at position 217 and introduces a premature stop
codon at position 224, generating a truncated protein with only
223 amino acids. The c.487C4T (p.Q163X) mutation is a non-
sense mutation found in the second exon of PRRT2, which sub-
stitutes the codon for Q163 (CAG) with a stop codon (TAG) and
generates a truncated protein with only 162 amino acids. As a
result, both mutant proteins lack the transmembrane segments.
To conﬁrm PRRT2 as the causative gene of PKD, we used
Sanger sequencing to screen all members of Families A and B
with respective variants (c.649_650InsC in Family A and
c.487C4T in Family B). As shown in Fig. 1, all ﬁve clinically af-
fected subjects, but none of those who were unaffected in Family
A, carried the heterozygous c.649_650InsC mutation. Similarly, all
seven patients, but none of the unaffected individuals in Family B,
were heterozygous for the c.487C4T mutation. Thus, the muta-
tions in PRRT2 completely co-segregated with the PKD phenotype
within these two families.
Table 2 Two-point logarithm of odds scores between
the disease locus and 11 microsatellite markers on
chromosome 16 in Families A and B
Marker LOD score at y =*
0.0 0.1 0.2 0.3 0.4 0.5
D16S3041 10.85 1.48 0.57 0.17 0.00 0.00
Family A 4.71 0.45 0.20 0.08 0.02 0.00
Family B 6.14 1.03 0.37 0.09 0.02 0.00
D16S403 8.14 0.28 0.58 0.54 0.34 0.00
Family A 4.42 0.22 0.01 0.05 0.05 0.00
Family B 3.72 0.49 0.59 0.49 0.28 0.00
D16S401 2.99 0.97 0.90 0.67 0.37 0.00
Family A 0.87 0.74 0.59 0.42 0.23 0.00
Family B 3.86 0.23 0.31 0.25 0.14 0.00
D16S409 3.77 3.14 2.45 1.68 0.84 0.00
Family A 0.86 0.73 0.58 0.41 0.22 0.00
Family B 2.90 2.41 1.87 1.26 0.62 0.00
D16S3136 1.47 1.20 0.91 0.59 0.28 0.00
Family A 0.87 0.74 0.59 0.42 0.23 0.00
Family B 0.60 0.47 0.32 0.17 0.05 0.00
D16S2623 1.91 1.88 1.56 1.10 0.57 0.00
Family A 1.47 1.20 0.91 0.59 0.28 0.00
Family B 0.44 0.68 0.65 0.51 0.30 0.00
D16S419 2.22 1.87 1.64 1.15 0.56 0.00
Family A 3.83 0.25 0.30 0.22 0.10 0.00
Family B 01.6 1.62 1.34 0.93 0.46 0.00
D16S415 1.89 1.82 1.46 0.99 0.47 0.00
Family A 0.87 0.70 0.52 0.34 0.17 0.00
Family B 1.02 1.13 0.95 0.65 0.31 0.00
D16S3057 1.61 1.63 1.35 0.95 0.49 0.00
Family A 1.47 1.20 0.90 0.59 0.28 0.00
Family B 0.14 0.42 0.44 0.37 0.22 0.00
D16S514 2.53 1.05 1.18 0.95 0.53 0.00
Family A 1.17 0.95 0.70 0.45 0.20 0.00
Family B 3.70 0.1 0.47 0.50 0.33 0.00
D16S503 0.59 0.46 0.17 0.17 0.05 0.00
Family A 0.59 0.46 0.31 0.17 0.05 0.00
Family B 0.00 0.00 0.00 0.00 0.00 0.00
LOD = logarithm of odds; * = different recombination fraction.
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quenced all the exons and ﬂanking introns of the PRRT2 gene
of patients and unaffected members in another three unrelated
PKD pedigrees. As shown in Fig. 2, the c.649_650InsC
(p.P217fsX7) insertion was identiﬁed in Families C and D. We
also identiﬁed a missense mutation c.796C4T (p.R266W) in
Family E (Fig. 3D). The c.796C4T (p.R266W) is a missense
mutation found in the second exon, causing an arginine to
tryptophan substitution at codon 266 (Fig. 3D and E). As shown
in Fig. 2, these two variants also co-segregated with the PKD
phenotype in Families C–E. Additionally, these three mutations
were not detected in 500 unaffected control individuals
of matched geographical ancestry, as examined by Sanger
sequencing.
Discussion
PKD is a neurological disorder with dystonic posturing, chorea,
athetosis, ballism or a combination of these hyperkinetic symp-
toms (Kertesz, 1967; Goodenough et al., 1978; Demirkiran and
Jankovic, 1995; Bruno et al., 2004). We have identiﬁed PRRT2 as
the causative gene of PKD. PRRT2 had three different mutations,
c.487C4T (p.Q163X), c.649_650InsC (p.P217fsX7) and
c.796C4T (p.R266W), in ﬁve different autosomal dominant
PKD families. Several lines of evidence supported the causal role
of PRRT2 in PKD: (i) the linkage analysis in two families mapped
locus of our PKD families to a pericentromeric region (16p12.1–
q12.1) on chromosome 16; (ii) PRRT2 was the only gene with
mutations shared by all three patients in the linkage region;
(iii) two additional PKD families (Families C and D) carried the
insertion mutation (c.649_650InsC), and a third PKD family
(Family E) carried a different missense mutation (c.796C4T); (iv)
all the mutations co-segregated with the phenotype; and (v) ab-
sence of such mutations in 500 normal unaffected individuals of
matched geographical ancestry.
Although all of the patients with PKD in our study had muta-
tions in PRRT2, their clinical features, except the core syndrome,
varied among families. For instance, the insertion mutation
(c.649_650InsC) was found in Families A, C and D, but the clinical
manifestation of these three families varied from each other.
Family A had two patients (Patients III: 2, III: 5) who presented
with infantile convulsion and choreoathetosis, whereas the
patients in Families C and D did not report any other history of
intermittent neurological disorder. Families C and D also had dif-
ferent presentations. Family C presented with dystonia in lower
limbs; however, Family D presented mainly with dystonia in upper
limbs. It is possible that other unappreciated gene mutations may
contribute to the heterogeneity of PKD phenotypes. Indeed,
Figure 2 Pedigrees of three additional families with PKD. Subjects in Families C–E were identiﬁed by the Arabic numerals above the
symbol, and Roman numerals denote the generation. Symbols are the same as in Fig. 1.
Novel PKD causative gene Brain 2011: 134; 3490–3498 | 3495Figure 3 Mutations of the PRRT2 gene. (A) Sanger sequencing of codons 214–220 of PRRT2 in a wild-type (WT) subject and (B) the
c.649_650InsC (p.P217fsX7) mutation. The mutation results in a frame-shift, which generates different sequences starting at position 217
and introduces a premature stop codon at position 224. (C) Sanger sequencing of codons 162–164 of PRRT2 in a wild-type subject (left)
and an affected subject (right) with c.487C4T (p.Q163X) mutation. (D) Sanger sequencing of codons 265–267 of PRRT2 in a wild-type
subject (left) and an affected subject (right) with c.796C4T p.R266W mutation. The mutant sites are indicated by red triangles in B–D.
(E) Schematic diagram of PRRT2 gene and wild-type or mutant PRRT2 protein. The three mutations identiﬁed in this study are indicated
with arrows. PRRT2 gene consists of four exons. PRRT2 protein has two domains: two low complexity segments followed by two
transmembrane segments. All three mutations are located upstream of the coding region of the ﬁrst transmembrane segment of PRRT2
protein. (F) The diagram of chromosome 16 indicating the relative position of PKD locus. The minimal linkage interval of PKD is 19.16 cM
between D16S401 and D16S2623 on chromosome 16p12.1-q12.1. The PRRT2 position is indicated with a red triangle.
3496 | Brain 2011: 134; 3490–3498 J.-L. Wang et al.we also found abundant novel mutations and SNPs in other genes
by exome sequencing in every patient with PKD (Table 3).
PRRT2 is a member of the transmembrane protein family,
including PRRT1-4. Interestingly, two of the mutations identiﬁed
in this study (p.Q163X and p.P217fsX7) resulted in truncated
PRRT2 proteins lacking the transmembrane domain. These trun-
cated proteins cannot anchor to the membrane and may be
loss-of-function. However, similar to some soluble membrane re-
ceptors, the soluble PRRT2 may still preserve binding ability to the
interactive proteins or ligands and attenuate their binding to the
wild-type PRRT2, i.e. dominant negative effect (Celli et al., 1998).
Nevertheless, the exact underlying molecular mechanism as to
how these mutations caused PKD, either haploinsufﬁciency or
dominant negative effect, requires further investigation.
There is a limited amount of research regarding the function of
PRRT2; however, some indirect evidence suggested its role in the
pathogenesis of PKD. First, PRRT2 was found to be mainly ex-
pressed in the basal ganglia (http://human.brain-map.org), a brain
area possibly involved in the PKD pathogenesis (Hamano et al.,
1995; Hayashi et al., 1997; Ko et al., 2001; Shirane et al., 2001;
Volonte et al., 2001; Iwasaki et al., 2004). Secondly, SNAP25, an
interactive protein of PRRT2, is also expressed in the brain, espe-
cially the basal ganglia (Stelzl et al., 2005). Third, SNAP25 partici-
pates in the regulation of neurotransmitter release (Graham et al.,
2002). Finally, recent research studies have revealed that SNAP25
might be involved in the aetiology of the attention-deﬁcit hyper-
activity disorder (Gizer et al., 2009; Banaschewski et al., 2010),
whereas the core features of PKD are also a paroxysmal hyper-
kinetic (Demirkiran and Jankovic, 1995).
Since the ﬁrst description by Kertesz (1967), PKD has been widely
studied. However, the mechanism is still unclear. Here, we have
identiﬁed PRRT2 as the ﬁrst causative gene for PKD, warranting
future research to understand the pathogenesis of PKD.
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